Pleurodesis

The objective of this study was to compare the effectiveness of bleomycin as a sclerosing agent with povidone-iodine with respect to efficacy, cost, accessibility, safety, ease of administration, and number of doses for complete response.        

Forty participants were assigned into two treatment groups of bleomycin treatment or povidone-iodine treatment via block randomization. A 28Fr. chest tube was placed in all patients at the bedside under local anesthesia with opioids given for pain. The following day, both groups had a sclerosing agent instilled in the chest tube for one hour; bleomycin at 1 mg/kg in 60 mL saline in the study group and povidone-iodine 10%, which was diluted to obtain a final concentration of 2.5% povidone-iodine in the control group. Both groups had 5 mL of 2% lidocaine solution added to the sclerosing agent. In both groups, the chest tubes were clamped for one hour and then connected to water seal. All patients were admitted to the same unit in the hospital and experienced the same post-pleurodesis respiratory and pain management protocols. The chest tube remained in place until output decreased to 200 mL; if high output persisted more than 10 days, a Heimlich valve was placed and patients were discharged from the hospital. Chest x-rays were obtained post-chest tube removal and at 30 days post-procedure to evaluate size of pleural effusions. Pain and dyspnea after drainage ratings were recorded at discharge and at 30 days post-op. 

The sample was comprised of 39 patients.

Key disease characteristics included

• Biopsy- or cytology-proven malignant pleural effusions with a variety of types of cancer
• Effusions previously treated with and showing improvement with thoracenteses but recurrent or symptomatic when entered in study.

Key sample characteristics included

• Symptomatic benefit from thoracenteses
• Chest radiograph confirming lung expansion of 90% or more after therapeutic thoracenteses
• Karnofsky performance status index greater than or equal to 70
• No one with comorbidities that would exclude them from general anesthesia
• No bleeding disorders, massive skin infiltration, or active infectious disease.
   

This single-site study was conducted in the inpatient unit at Valiasr Hospital in Tehran, Iran.

• Patients were undergoing long-term follow-up care.
• The study has clinical applicability for end-of-life and palliative care.
   

The study was a randomized clinical trial.

• Chest tube placement, +/- Heimlich valve    
• Numeric pain scale
• Chest x-ray
• Dyspnea scale (1–10)
   

• According to author reports, the groups were equivalent in demographic variables, but this data was not visible to the reviewer.
• No significant difference was seen between groups with respect to age, duration of thoracostomy, volume of pleural effusion, dyspnea score after drainage, fever, and pleural effusion after drainage, discharge, and one month later.
• Patients in the bleomycin group had significantly lower dyspnea scores at the one-month follow-up time compared to the povidone-iodine group.
• Complete pleurodesis occurred in 79% of the bleomycin group and 75% of the povidone-iodine group, which is not a significant difference in treatment results.

• Bleomycin is more effective at long-term dyspnea management based on one-month follow-up reports.
• No differences were observed between groups based on pain score following procedure, dyspnea at discharge, or reoccurrence of pleural effusion at the one-month follow-up visit. 
• Neither method demonstrated extremely superior results and appear similar in overall effects.

• The study had a small sample size of less than 100 patients.
• Groups were not matched by age and sex.
   

When compared with povidone-iodine, bleomycin offers the advantage of being more effective for dyspnea symptoms one month post-procedure. However, both methods appear similar in terms of pain scores, dyspnea at discharge, and recurrence of pleural effusions at one-month follow-up. For patients with concerns of iodine absorption or side effects, bleomycin would be a comparable sclerosing agent.

The objective of the study was to determine if indwelling pleural catheters (IPCs) are more effective than talc slurry pleurodesis via chest tube for relief of dyspnea.

Patients with symptomatic malignant pleural effusion requiring pleurodesis were randomized to either IPC or talc pleurodesis. IPCs were inserted, initial large-volume drainage was performed, and caregivers were trained in IPC management. Drainage was advised to be done three times weekly. The IPC was removed if significant drainage stopped for at least four weeks, with no evidence of fluid reaccumulation. Patients in the talc group were hospitalized and had percutaneous chest tube insertion and talc slurry pleurodesis with 4 g sterile high-grade talc, following published treatment guidelines. Patients were followed up for 12 months after randomization. Dyspnea measurement was recorded daily for 42 days and then at 10, 14, 18, 22, and 26 weeks, and at 9 and 12 months.

• The sampe was comprised of 96 patients.
• The mean patient age was 76 years (SD = 11.5 years).
• Of the 96 patients, 43.5% were males and 56.5% were females.
• Various cancer types were included in the sample, but breast and lung were most frequent.
• The average size of effusion on radiography as a hemothorax was 51% in the IPC group and 49% in the talc group.
   

The study was conducted in multiple settings in the United Kingdom.

• Patients were undergoing late effects and survivorship care.
• The study has clinical applicability for palliative care.

The study was an unblinded, randomized controlled trial.

• 100 mm Visual Analogue Scale (VAS) for dyspnea
• EORTC - Quality of Life Questionnaire
• Complication recording
• Use of healthcare resources
   

• No significant difference in dyspnea was observed between groups.
• Dyspnea declined in both groups, with a mean decrease of 37.0 mm with IPC and 30.2 mm with talc. 
• At 6 months, a clinically significant decrease was seen in dyspnea in the IPC group compared to the talc group ( - 14.0 mm, p = .01). 
• Over 12 months, the IPC group spent an average of one day in the hospital for drainage or complications, compared to an average of 4.5 days in the talc group (p < .001).
• Global quality of life improved in both groups, with no significant difference between groups at any time point.
• In the IPC group, 40% experienced any adverse event, compared to 13% in the talc group (p = .002). 
• No difference in serious adverse events was observed between groups. 
• Pleural infections occurring with IPCs were asymptomatic and treated with oral antibiotics, and no IPC had to be removed for infection.

• Both talc pleurodesis and IPC were effective in reducing dyspnea in patients with malignant pleural effusion. 
• No significant difference in effectiveness was seen between the two approaches.
• IPCs reduce hospitalization time but are associated with more adverse events.

Because it was unblinded, the study had the risk of bias.

• Both approaches demonstrated effectiveness for reducing dyspnea in this group of patients. 
• Patient selection for IPC use needs to include consideration of caregiving needs and capabilities to manage the catheter, given the tendency for higher adverse events with its use.

The objective of the study was to compare tunneled pleural catheter drainage (TCD) to bedside talc pleurodesis (TP) via chest catheter for efficacy in controlling symptomatic unilateral malignant pleural effusions (MPE).

Randomized patients received one of two methods (TP or TCD) for pleural drainage then were followed up for 60 days. For the TP procedure, a single dose of 4–5 g of sterile talc slurry in 100 mL of saline was infused into the pleural space with a chest catheter. Placement was confirmed on a chest x-ray. Talc was administered within 36 hours of tube placement. The tube remained clamped for two hours for talc distribution. When the chest drainage decreased to 150 mL/24 hours, pleurodesis was assumed and the tube was removed. TP was performed on an inpatient basis. For TCD, catheters were drained daily with drainage bottles. No more than 1,000 mL were drained at a time, other than during the initial drainage. A chest x-ray was taken within 36 hours of initial drainage and the patient, a caregiver, or a visiting nurse drained the catheter daily after that. The catheter was removed when the drainage volume was less than 30 mL each day over three consecutive days. TCD is generally an outpatient procedure.

• The sample was comprised of 57 patients aged 60–67 years.
• Of the 57 patients, 45%–55% were males and 39%–61% were females.
• Patients had a performance status of 0 to 2 with no active pleural infection, talc allergy, or other indications to talc use.
• Lung cancer (62%) and breast cancer (12%) were the most common malignancies.
• The study originally planned 530 total patients for 90% power to detect differences in efficacy between the two methods of pleural drainage.
• Trapped lung was not recommended for randomized therapy, as TCD may be a better therapy option.

The study was conducted in 21 comprehensive cancer centers—17 cases were conducted at one instution, and 1–7 cases were conducted at each of the other institutions.

• Patients were undergoing multiple phases of care.
• The study has clinical applicability for elder care and palliative care.

The study was a prospective, randomized phase III trial.

• Lung re-expansion was determined by the treating physician using serial chest x-rays.
• Condensed Memorial Symptom Assessment Scale form (specific elements: performance status, dyspnea scale, physical function, social life, and overall quality of life) measured quality of life and specific symptoms or functionality.

• No statistical differences in lung expansion were noted between the two treatment arms, but it improved from baseline in both cases.
• The odds ratio for TCD success was five times higher than TP, and patients with good expansion experienced better success (odds ratio, 5; 95% CI, 1–25; P = .053).
• Pleurodesis occurred in 86.2% of patients treated with TP, compared with 68.0% of those treated with TCD (P = .1883).
• Therapy-related complications were low but were higher in the TCD arm.
• Recurrent dyspnea was seen only in TP cases, and dyspnea was statistically better in patients treated with TCD (8.7 vs. 5.9; P = .036) even after adjusting for baseline dyspnea score, initial drainage, gender, inpatient status, and performance status at baseline.
• No relationship was seen between baseline dyspnea score and lung expansion at any of the three points; however, 30-day dyspnea-free exercise and all quality-of-life measures correlated significantly with lung expansion.

• TCD is preferred for patients with complicated effusions or when the lung may be trapped.
• Although TCD prolongs therapy, this added duration may maintain lung expansion and improve quality-of-life parameters.
• Lung expansion may be an unreliable indicator of the benefits of pleural drainage.
• TCDs in this study may more predictably relieve dyspnea.
• The study had to be closed early because patients had a strong preference for treatment (inpatient vs. outpatient) and refused randomization.

• The study had a small sample size of less than 100 patients.
• The study had a risk of bias because of no blinding and its sample characteristics.
• Accrual was far less than anticipated due to patient preferences interfering with patient consent to randomization.
• Refusals to participate may have influenced the final study population, as evidenced by lower-than-anticipated success of talc pleurodesis intervention.
• The study does not describe that “malignant effusion” was validated cyopathologically.

• TCD and TP are both common strategies to manage malignant pleural effusion.
• Similar lung expansion appears to be able to be achieved with both techniques in patients with uncomplicated pleural effusion, and the selection of method may be based upon patient preference.
• Nurses should ensure that patients are thoroughly informed of therapeutic options to make the best decision for their circumstances.
• In cases in which patients experience distress form dyspnea at baseline, they may experience better symptom relief with the TCD method of managing malignant pleural effusions.

To evaluate outcomes after video-assisted thoracic surgery pleurodesis among intubated patients and unintubated patients under local anesthesia

Consecutive patients who received unintubated video-assisted pleurodesis were matched with patients who preferred general anesthesia and were intubated for the procedure. Data were obtained from a retrospective review. Cases were matched on age, gender, performance status, history, and type of tumor. Patients with extrathoracic metastases were excluded. Patients received intercostal blocks and sedation with remifentanil. For the intubated group, general anesthesia was induced with propofol, fentanyl, and vecuronium. Talc was used for pleurodesis in both groups. Postoperative management was the same in both groups.

• N = 462–231 (intervention group)  
• MEAN AGE = 64.3 years
• MALES: 55%, FEMALES: 45%
• KEY DISEASE CHARACTERISTICS: Multiple tumor types with secondary pleural malignancy; most common was lung cancer followed by breast cancer

• SITE: Single site  
• SETTING TYPE: Inpatient  
• LOCATION: Italy

• PHASE OF CARE: Active antitumor treatment
• APPLICATIONS: Palliative care 

Retrospective, descriptive study with a matched control comparison

• European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ C30)

Anesthesia time (p < 0.0001) and recovery room time (p = 0.0002) were significantly shorter in the unintubated group. Postoperative hospital stays were 1.8 days shorter on average in the unintubated group (p = 0.011), and postoperative morbidity (p = 0.042) and mortality (p = 0.017) were lower in the unintubated group. Pleurodesis was successful in more than 83% of patients in both groups, and costs were lower in the unintubated group. Physical function (p < 0.05) and dyspnea (p < 0.01) were more improved in the short-term among the unintubated patients. There was a higher rate of major subcutaneous emphysema in the unintubated group. There were no differences between the groups in effusion-free time or overall survival.

Video-assisted pleurodesis under local anesthesia without the need for intubation was associated with shorter postoperative hospital stays, fewer short-term postoperative issues, and improved dyspnea compared to similar patients who received traditional pleurodesis under general anesthesia.

• Risk of bias (no blinding)
• Risk of bias (no random assignment)
• Other limitations/explanation: The study included people with good performance statuses, so findings may not be applicable to those with poorer physical conditions overall.

The performance of pleurodesis under local anesthesia with video-assisted thoracic surgery was shown to improve short-term postoperative outcomes compared to procedures done under general anesthesia in this study. There were some differences in postoperative complications between patients who had general anesthesia versus those who did not, so nurses need to be aware of the potential differences in complications according to the type of procedure done and assess patients accordingly. The applicability and safety of this approach in patients with very poor overall performance status is not clear.

The objective of the study was to compare the efficacy and safety of 10% povidone-iodine and thoracoscopic talc insufflation for pleurodesis of recurrent malignant pleural effusions due to metastatic breast cancer.

Forty-two participants were randomized into two groups. Patients assigned to Group A received video-assisted thoracoscopic (VATS) drainage, mechanical adhesiolysis, and 4 g of talc poudrage, while the 20 patients assigned to Group B received VATS drainage, mechanical adhesiolysis, bedside pleurodesis with 20 mL of 10% povidone-iodine diluted in 30 mL of normal saline. Therapeutic thoracentesis was performed in all participants, and pleural fluid volume was recorded and sent for biochemical (pH, LDH, glucose), bacteriologic, and cytologic evaluation. All patients were scheduled for a follow-up every three months at which symptoms and chest x-rays were evaluated, and efficacy of pleurodesis was gauged on three levels: complete (absence of pleural fluid reaccumulation), partial (residual pleural fluid or reaccumulation that remained asymptomatic and not requiring thoracentesis), or failed (necessitating pleural procedures). Success was defined as a normal chest x-ray or radiologic reaccumulation of pleural fluid without recurrence of dyspnea or need for thoracentesis. Repeated ultrasound-guided thoracentesis was provided for patients with failed pleurodesis and reaccumulation of effusion at weekly intervals, and a PleurX^® catheter was offered for home management of effusions when required.

• The study reported on a sample of 42 patients.
• In Group A, the mean age was 48 years (SD = 9 years), and the range was 29–64 years.
• In Group B, the mean age was 50.2 years (SD = 7 years), and the range was 32–62 years.
• Data were not available to determine the percentage of males and females.
• Participants had malignant pleural effusion secondary to metastatic breast cancer.
• All patients either had either metastasis as their first presentation or had relapsed after chemotherapy during their follow-up.
• Patients were excluded from the study if they had a performance status greater than three, known allergies to iodine, a trapped lung, no change in the Medical Research Council (MRC) dyspnea scale after thoracentesis, pleural fluid pH less than 7.2 or glucose less than 60 mg/dL, and an extrathoracic metastasis.
• Both groups received the same protocol for adjuvant chemotherapy (i.e., 5FU, Adriamycin^®, and chlophosphamide (FAC), or docetaxel).
• No difference in preoperative demographic and clinical details between the two groups were noted.
   

This single-site study was conducted in an outpatient setting in the Department of Chest Medicine and Cardiothoracic Surgery in Cairo University Hospitals.
 

• Patients were in the transition phase after initial treatment.
• The study has clinical applicability for end-of-life and palliative care and late effects and survivorship.
   

The study was a prospective, randomized controlled trial.

• Medical Research Council (MRC) dyspnea scale to assess breathlessness
• Performance status scale (ECOG) to assess functional ability
• Diagnostic thoracentesis
   

Dyspnea and cough symptoms were improved in all patients after drainage and pleurodesis, and no mortality related to the procedure or perioperative mortality were observed. Survival rates between the two groups and totally at follow-up were 32 patients (76%) at eight months, 22 patients (52%) at two years, and 10 patients (23%) at four years. All had good outcomes with no bleeding complications and were discharged when both radiologic and clinical evidence confirmed complete resolution of pleural effusion. Group B experienced a significantly lesser post-procedural hospital stay (mean 5.7 days [SD = 2 days]) than Group A (mean 4.5 days [SD = 1.1 days]) (p = 0.009). During early follow-up in Group A, successful/complete response was achieved in 19 patients (87%), failure in 2 patients (9%), and partial response with radiologic reaccumulation at two months post-procedure but remaining asymptomatic during the 14 months’ follow-up. Early follow-up in Group B resulted in 17 (85%) complete response, no partial response, and three failures (15%) with recurrence of dyspnea at 33, 41, and 49 days respectively. No loculations were observed in Group B, thus a small-bore chest tube was placed and iodine was used again. In Group A, observed loculations were repeatedly aspirated with an ultrasound guide, and when repeated reaccumulation was experienced, an ultrasound-guided PleurX^® catheter was offered. No recurrence was detected at more than six months during follow-up, and no statistical difference between long-term success (four years) rates in Groups A (91%) and B (85%) were observed. Complications of pleuritic pain were observed in four participants of Group A (18%) but none in Group B, and fever was observed in four participants (18%) in Group A, and one participant (5%) in Group B.

Authors concluded that povidone-iodine pleurodesis is a safe and effective alternative to talc pleurodesis in the prevention of recurrent malignant pleural effusion at 30 days post-procedure. Additionally, while chest pain and fever are the most common adverse effects of pleurodesis, those in the iodine-povidone population (Group B) experienced less analgesic requirements and reports of fever, albeit at no statistical significance. Authors also emphasized that the dose of 10% povidone-iodine was administered in dilute form, thereby significantly increasing povidone safety with decreased toxicity when compared to other studies.

• The study had a small sample size, with less than 100 participants.
• The study results are only significant to a population of patients with malignant pleural effusion secondary to metastatic breast cancer; more research is warranted for efficacy among other population types.
• The clinical practice of providing mechanical adhesiolysis through the VATS procedure may have contributed to successful pleurodesis in both groups; true translation of this evidence would require performing a VATS procedure prior to the instillation of povidine-iodine, which is an uncommon practice. (Patients usually have a VATS procedure with talc insufflations or a chest catheter bedside procedure but not a surgical procedure followed by a bedside procedure.)
• Statistical analysis was limited by a lack of computed confidence intervals to safely exclude clinically relevant differences, as well as a lack of survival analysis.
   

Given its good success rate and fewer complications, povidone-iodine appears to be a successful, safe, and cost-effective alternative to talc pleurodesis for palliative management of malignant pleural effusion stemming from metastatic breast cancer.

To study the effect of using streptokinase in pleurodesis for the management of multiloculated malignant pleural effusion (MPE)

Patients were randomly assigned to either the treatment group, which received streptokinase 250,000 IU into pleural space via a thoracostomy tube, or the control group, which received 50 ml of saline at 24, 36, 48, and 60 hours post tube placement. Data were collected regarding volume of pleural drainage, chest computerized tomography (CT) images before and after treatment, dyspnea before and after treatment, and recurrence rate of effusion. Coagulation profiles were assessed prior to administering streptokinase, and all patients had a chest CT to locate the largest locule of fluid. A 20 Fr chest tube was placed and connected to an underwater seal at a continuous suction of -20 cm H₂O. For both groups, daily pleural drainage at 48 and 72 hours were measured. After the third day, a CT thorax was taken and read by one radiologist. On the fourth day, pleurodesis was performed using 4 g of sterile talc. On the fifth day, the chest tubes were removed. Patients that continued to be dyspneic (oxygen dependent) were not discharged from the hospital, and nondyspneic patients were discharged (n = 29) and later evaluated in regard to whether or not they required a repeat pleural catheterization within 30 days because of the redevelopment of dyspnea.

• N = 40   
• MEAN AGE = 57.8 years
• MALES: 60%, FEMALES: 40%
• CURRENT TREATMENT: Immunotherapy
• KEY DISEASE CHARACTERISTICS: All had multiloculated MPE; 40% had diagnosis of lung cancer.
• OTHER KEY SAMPLE CHARACTERISTICS: Other cancer diagnoses included breast, colon, ovarian, lymphoma, and others.

• SITE: Not stated/unknown   
• SETTING TYPE: Not specified    
• LOCATION: Istanbul, Turkey

• PHASE OF CARE: Multiple phases of care
• APPLICATIONS: Palliative care 

• Randomized, double-blind, placebo-controlled trial

Measurements were given as mean and standard deviations, and the two groups were compared using the Mann-Whitney U test. The chi-square test was used to compare the improvement scores of the groups via CT evaluation, dyspnea scores, and recurrence rate. SPSS, version 15.0, was also used.

The differences between drainage volumes between groups was statistically significant. Mean drainage volumes for the intervention group versus the control was 493/248 at 24–48 hours, 446/198 at 48–72 hours, and 939/446 overall (p <  0.001). Dyspnea symptoms (defined as oxygen dependent) improved in 90% of the fibrinolytic group and 55% of the control group (p = 0.03). Post discharge of 29 nondyspneic (nonoxygen dependent) patients, 11% of fibrinolytic group had recurrence versus 45% of the control group (p = 0.07). A thorax CT demonstrated a 40% or greater improvement in 85% of the fibrinolytic group and 35% of the control group (p = 0.001).

The treatment group receiving streptokinase via a chest tube prior to pleurodesis had greater improvement in symptoms of dyspnea, greater reduction in volume of MPE, and a lower rate of effusion recurrence.

• Small sample (< 100)
• Measurement/methods not well described

The use of fibrinolytic agents for management of MPE prior to pleurodesis may improve outcomes for reducing dyspnea and reducing recurrence post-pleurodesis leading to enhanced patient quality of life. Additional large-scale studies are indicated for validation. Having a basic understanding of pathophysiology and rationale is important for self-knowledge, patient monitoring, and education in settings using fibrinolytic therapy to treat MPE.

To evaluate patient-reported satisfaction with treatment, quality of life (QoL), and dyspnea outcomes for four treatment strategies for malignant pleural effusion.

Four treatment regimens (indwelling pleural catheter [IPC] alone, video-assisted thoracic surgery [VATS] and IPC, bedside chest tube and talc slurry; and VATS with talc poudrage) for malignant pleural effusion (MPE) were evaluated using patient-reported outcome tools. The primary outcome of treatment satisfaction was measured immediately after treatment, as well as two and six weeks post-completion using the Functional Assessment of Chronic Illness Therapy-Treatment Satisfaction (FACIT-TS) tool. Secondary outcomes of improvement in dyspnea and QoL were measured at baseline, two, and six weeks post-treatment. Functional Assessment of Chronic Illness Therapy-Palliative (FACIT-Pal) was used to measure QoL; the London Chest Activity of Daily Living scale was used to measure dyspnea.

• N = 104   
• AGE: Median age = 61, range = 26-89
• MALES: 36%  
• FEMALES: 64%
• CURRENT TREATMENT: Other
• KEY DISEASE CHARACTERISTICS: Confirmed diagnosis of cancer with symptomatic pleural effusion confirmed on chest x-ray included; those with endobronchial obstruction, empyema, allergy to talc, or prior treatment for ipsilateral pleural effusion excluded. 
• OTHER KEY SAMPLE CHARACTERISTICS: Must be able to read and write in English. Lung cancer most common, breast cancer second most common diagnoses

• SITE: Multi-site   
• SETTING TYPE: Inpatient urban hospitals
• LOCATION: Canada

• PHASE OF CARE: Multiple phases of care
• APPLICATIONS:  Palliative care

Prospective cohort study

Functional Assessment of Chronic Illness Therapy-Palliative (FACIT-Pal) was used to measure health-related QoL; the London Chest Activity of Daily Living scale was used to measure dyspnea; Functional Assessment of Chronic Illness Therapy-Treatment Satisfaction (FACIT-TS) was used to measure treatment satisfaction. Post-treatment pain measured on 0-10 scale, and ECOG performance status measurement was added mid-study.

No statistical difference in patient-reported outcomes was identified when comparing results for each of the four treatment modalities: indwelling pleural catheter (IPC), video assisted thoracic surgery (VATS), chest tube and talc slurry; and VATS talc poudrage. There was a statistically significant trend of improvement in overall FACIT-PAL score (p < 0.0001) and trend in decreasing breathlessness measured with both London Chest Activity Daily Living scale (p = 0.003) and FACIT-Pal shortness of breath score (p = 0.0007) when evaluating all study participants as a whole; there was no statistical difference between groups. Treatment satisfaction at six-week point was highest with VATS plus pleurodesis group and lowest with chest tube group; however, difference was NOT statistically significant.

Each of the treatment options for treating malignant pleural effusions are efficacious in improving health-related QoL and decreasing breathlessness with no statistically significant difference in patient-reported satisfaction when comparing each intervention.

• Risk of bias (sample characteristics)
• Key sample group differences that could influence results
• Measurement validity/reliability questionable
• Other limitations/explanation: The subject accrual period was from 2007 to 2013; variability in individuals performing interventions and setting (some outpatient, some inpatient). Difficulty recruiting from multicultural population due to inability to read/write in English influenced participant selection. Sample size small at 104. London Chest Activity of Daily Living scale reliability and validity only tested with COPD population, not MPE.

Nurses educating individuals living with symptomatic malignant pleural effusions need to understand and share data regarding the experience of other patients; patients will benefit from knowledge that other individuals with MPE report an improvement in health-related QoL and a decrease in breathlessness regardless of MPE treatment option utilized. More research is needed in development of measurement tools for breathlessness in individuals with MPE. Additional studies with larger sample sizes are needed to evaluate treatment of dyspnea in patients with cancer because dyspnea is commonly experienced by individuals with advanced disease.